Lupaneta Pack is a drug owned by Abbvie Endocrine Inc. It is protected by 1 US drug patent filed in 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 13, 2016. Details of Lupaneta Pack's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US6036976 | Sustained release microspheres and preparation thereof |
Dec, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Lupaneta Pack is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lupaneta Pack's family patents as well as insights into ongoing legal events on those patents.
Lupaneta Pack's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lupaneta Pack's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 13, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lupaneta Pack Generics:
There are no approved generic versions for Lupaneta Pack as of now.
About Lupaneta Pack
Lupaneta Pack is a drug owned by Abbvie Endocrine Inc. Lupaneta Pack uses Leuprolide Acetate; Norethindrone Acetate as an active ingredient. Lupaneta Pack was launched by Abbvie Endocrine in 2012.
Approval Date:
Lupaneta Pack was approved by FDA for market use on 14 December, 2012.
Active Ingredient:
Lupaneta Pack uses Leuprolide Acetate; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Leuprolide Acetate; Norethindrone Acetate ingredient
Dosage:
Lupaneta Pack is available in injectable, tablet form for intramuscular, oral use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
3.75MG/VIAL,N/A;N/A,5MG | INJECTABLE, TABLET | Discontinued | INTRAMUSCULAR, ORAL |
11.25MG/VIAL,N/A;N/A,5MG | INJECTABLE, TABLET | Discontinued | INTRAMUSCULAR, ORAL |